StonvexLoading…
StonvexStonvexStonvexCore line items from DDS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-01-31 | Annual 2025 2025-02-01 | Annual 2024 2024-02-03 | Annual 2023 2023-01-28 |
|---|---|---|---|---|
Revenue | $6.47B | $6.48B | $6.75B | $6.87B |
Operating Income | $694.48M | $729.70M | $916.62M | $1.11B |
Net Income | $570.19M | $593.48M | $738.85M | $891.64M |
EPS (Diluted) | $36.42 | $36.82 | $44.73 | $50.81 |
Total Assets | $3.51B | $3.53B | $3.45B | $3.33B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $861.46M | $717.85M | $808.29M | $650.34M |
Free Cash Flow OCF − CapEx | $623.63M | $609.58M | $750.65M | $828.29M |
Shares Outstanding | 15.65K | 16.12K | 16.52K | 17.55K |